Chemosensory loss in <scp>COVID</scp>‐19

Xu, Winnie; Sunavala‐Dossabhoy, Gulshan; Spielman, Andrew I.

doi:10.1111/odi.14300

Cited by 17 publications

(14 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omicron can also enter specific epithelial taste cells through ACE-2 receptor and destroy normal taste function [31] . Or by affecting the oral symbiotic flora to change the immune status and induce cytokine storms, ultimately damaging the taste nerve and destroying the taste function [32] . Although there is no effective treatment for sensory loss [27] , most patients (>95%) can recover completely or nearly completely within half a year after the acute phase [33] .…”

Section: Discussionmentioning

confidence: 99%

COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old — — A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China

Zhong

Yue

et al. 2023

Preprint

View full text Add to dashboard Cite

ObjectiveThis study attempted to explore the difference of clinical characteristics in H1N1 influenza infection and SARS-CoV-2 Omicron infection in people younger than 65 years old, in order to better identify the two diseases.MethodsA total of 127 H1N1 influenza patients diagnosed from May 2009 to July 2009 and 3265 patients diagnosed and identified as SARS-CoV-2 Omicron BA.2 variant from March 2022 to May 2022 were admitted in this study. Through the 1 : 2 match based on age (The difference is less than 2 years), gender and underlying diseases, 115 patients with H1N1 infection and 230 patients with SARS-CoV-2 Omicron BA.2 infection(referred to as H1N1 group and Omicron group) were included in the statistics. The clinical manifestations of H1N1 group were compared with those of Omicron group. Logistic regression was performed to analyze the possible independent risk factors of H1N1 group and Omicron group. And multiple linear regression was used to analyze the factors for time for nucleic acid negativization (NAN).ResultsThe median age of the two groups was 21 [11,26] years. Compared with the H1N1 group, the Omicron group had lower white blood cell count and CRP levels, less fever, nasal congestion, sore throat, cough, sputum and headache, while more olfactory loss, muscle soreness and LDH abnormalities. The Omicron group used less antibiotics and antiviral drugs, and the NAN time was longer (17 [14,20] VS 4 [3,5], P < 0.001). After logistic regression, it was found that fever, cough, headache, and increased white blood cell count were more correlated with the H1N1 group, while muscle soreness and LDH abnormalities were more correlated with the Omicron group. After analyzing the factors of NAN time, it was found that fever (B 1.529, 95 % CI [0.149,2.909], P = 0.030) significantly predicted longer NAN time in Omicron patients.ConclusionThis study comprehensively evaluated the similarities and differences in clinical characteristics between SARS-CoV-2 Omicron infection and 2009 H1N1 influenza infection, which is of great significance for a better understanding for these diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old — — A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China

Zhong

Yue

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“… 14 As of October 2022, there is disagreement about the therapeutic options for post-viral olfactory disorders such as those resulting from Coronavirus Disease 2019. 15 In our opinion, we are still a long way from a rational therapy recommendation that can claim to be a standard. 16 The commonly used therapy with a topical nasal corticosteroid (TNC) has an ambiguous grade of recommendation.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection

Schmidt¹,

Azar²,

Goektas³

2023

Ear Nose Throat J

View full text Add to dashboard Cite

Objective The benefit of a nasal corticosteroid in the treatment of persistent post-infectious smell disorders is not as clear in previous studies as is assumed for olfactory training. This study would therefore like to describe the treatment strategies using the example of a persistent olfactory dysfunction as a result of a proven infection with SARS-CoViD-2-virus. Methods Twenty patients (average age of 33.9 ± 11.9 years) with hyposmia were included in this study from December 2020 to July 2021. Every second patient received additionally a nasal corticosteroid. The two resulting randomized groups of equal size were screened with the TDI test, a 20-item taste powder test for the assessment of retronasal olfaction and otorhinolaryngological examination. The patients were asked to train twice daily using a standardized odor training kit and followed up after 2 months and 3 months, respectively. Results We documented a significant overall improvement in olfactory ability over the investigation period in both groups. While the TDI score steadily increased on average under the combination therapy, the rise under olfactory training alone was initially steeper. This short-term interaction effect over mean two months was not statistically significant. According to Cohen, however, a moderate effect (eta 2 = 0.055, Cohen`s d = 0.5) can still be assumed. This effect could be explained by a possibly higher compliance at the beginning of the sole olfactory training due to the lack of further drug treatment offers. When the training intensity decreases, the recovery of the sense of smell stagnates. Adjunctive therapy ultimately outweighs this short-term benefit. Conclusions The results reinforce the recommendation of early and consistent olfactory training on patients with dysosmia due to COVID-19. For continuous improvement of the sense of smell, an accompanying topical treatment seems at least to be worth consideration. The results should be optimized with larger cohorts and using new objective olfactometric methods.

show abstract

“…Olfactory dysfunction has been well documented across a number of respiratory pathologies, but gustatory dysfunction is remarkably uncommon—with minimal changes noted even with aging. Often, loss of flavor perception is due to loss of smell with preservation of actual taste 5…”

mentioning

confidence: 99%

“…Some patients reported a lasting loss of smell and taste even after resolution of the virus, which may result in reduced appetite and weight loss. Moreover, given the social associations with food, these symptoms can reduce the quality of life and lead to seclusion 5…”

mentioning

confidence: 99%

Use of Stellate Ganglion Block to Treat Anosmia and Dysgeusia Associated With COVID-19: A Narrative Review

Cheng,

Etigunta,

Patel

et al. 2023

Topics in Pain Management

View full text Add to dashboard Cite

Chemosensory loss in COVID‐19

Cited by 17 publications

References 68 publications

COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old — — A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China

COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old — — A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China

Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection

Use of Stellate Ganglion Block to Treat Anosmia and Dysgeusia Associated With COVID-19: A Narrative Review

Contact Info

Product

Resources

About